Physician profile
Dan A Martin
NPI 1508863267
$1,704.93
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $373 · 2020: $245 · 2021: $398 · 2022: $238 · 2023: $364 · 2024: $87.10.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $451.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $451.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $194.97 | 2021-2024 | |
| Novo Nordisk INC | $148.39 | 2019-2021 | |
| Lilly USA, LLC | $140.51 | 2020-2024 | Jardiance, Mounjaro, Emgality |
| Amgen INC. | $139.46 | 2020-2023 | Repatha, Otezla |
| Paratek Pharmaceuticals, INC. | $136.24 | 2023 | Nuzyra |
| Janssen Pharmaceuticals, INC | $128.68 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $110.60 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $103.38 | 2020-2023 | Verquvo, Belsomra |
| Exact Sciences Corporation | $88.02 | 2023-2024 | Cologuard Collection Kit |
| Allergan, INC. | $82.99 | 2019 | |
| Glaxosmithkline, LLC. | $80.60 | 2020-2023 | Trelegy Ellipta |
| Biohaven Pharmaceutical Holding Company LTD. | $75.63 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.07 | 2020-2021 | |
| Pfizer INC. | $55.88 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.34 | 2019-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiovascular Systems INC. | $20.54 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $17.83 | 2023 | Rexulti |
| Xeris Pharmaceuticals, INC. | $16.76 | 2021 | |
| Biogen, INC. | $15.53 | 2021 | |
| Astellas Pharma US INC | $12.18 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $12.04 | 2020 | |
| Horizon Therapeutics Plc | $11.92 | 2021 | |
| Esperion Therapeutics, INC. | $11.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dan Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.